Condition: Breast Cancer · ER Positive Breast Cancer · HER2-negative Breast Cancer · Sponsor: Abramson Cancer Center at Penn Medicine
This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.
This description comes directly from the study's public registry record.
Julia T. Lewandowski · 215-662-2861 · Julia.Lewandowski@Pennmedicine.upenn.edu
Jennifer Zhang, MD · 215-615-6810 · Jennifer.Zhang@Pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| Abramson Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05396612